Daniel W. Rea
Expertise in
7
conditions

Daniel W. Rea

Dudley Road, 
Birmingham, ENG, GB 
Expertise in
7
conditions
Dudley Road, 
Birmingham, ENG, GB 

Overview

Daniel Rea practices practicing medicine in Birmingham, United Kingdom.

Mr. Rea is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Cardiomyopathy Due to Anthracyclines, HER2 Negative Breast Cancer, Inflammatory Breast Cancer, and Mastectomy.

He is actively involved in clinical research, co-authoring 117 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Dudley Road, Birmingham, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Can Patients With Residual Cancer After Chemotherapy for Early Breast Cancer be Identified With Multiple Ultrasound-guided Biopsies?
Can Patients With Residual Cancer After Chemotherapy for Early Breast Cancer be Identified With Multiple Ultrasound-guided Biopsies?
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Procedure
The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study
The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study
Enrollment Status: Completed
Publish Date: May 04, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

117 Total Publications

UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.
UK recommendations for Ki-67 immunohistochemical staining and interpretation in breast cancer.
Journal: Histopathology
Published: July 18, 2026

Frequently Asked Questions about Daniel W. Rea

Is Daniel W. Rea a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Daniel W. Rea is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Daniel W. Rea participate in research or clinical trials?

Yes. Daniel W. Rea has published 117 articles and abstracts on conditions like Breast Cancer. You can view a list of Daniel W. Rea's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rea's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile